Skip to Main Content

Advertisement

Skip Nav Destination

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia

Blood Adv (2021) 5 (23): 5387–5395.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement